Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

BHVN

Biohaven Ltd

Mar 18 • 04:00PM ET

28.85

Dollar change -0.81
Percentage change -2.73	%

Healthcare • Biotechnology • USA • NYSE

Peers: VRTX AMGN REGN GILD BMRN NBIX ALNY INCY SRPT EXEL

| Held by: VTI VB IWM VBR VXF XBI IWO IBB VTWO SCHA

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-9.39	Insider Own	12.66%	Shs Outstand	101.22M	Perf Week	-1.90%
Market Cap	2.94B	Forward P/E	-	EPS next Y	-5.83	Insider Trans	0.85%	Shs Float	89.14M	Perf Month	-30.36%
Income	-846.42M	PEG	-	EPS next Q	-1.70	Inst Own	90.67%	Short Float	9.29%	Perf Quarter	-28.16%
Sales	0.00M	P/S	-	EPS this Y	26.44%	Inst Trans	7.91%	Short Ratio	8.07	Perf Half Y	-24.24%
Book/sh	4.18	P/B	6.90	EPS next Y	14.59%	ROA	-150.03%	Short Interest	8.28M	Perf Year	-48.87%
Cash/sh	4.76	P/C	6.05	EPS next 5Y	22.04%	ROE	-198.83%	52W Range	26.80 - 60.46	Perf YTD	-22.76%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-49.78%	ROI	-185.53%	52W High	-52.28%	Beta	3.96
Dividend TTM	-	Quick Ratio	3.49	Sales past 5Y	0.00%	Gross Margin	-	52W Low	7.65%	ATR (14)	2.11
Dividend Ex-Date	-	Current Ratio	3.49	EPS Y/Y TTM	-65.63%	Oper. Margin	-	RSI (14)	34.15	Volatility	4.77% 6.97%
Employees	256	Debt/Eq	0.09	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.12	Target Price	62.20
Option/Short	Yes / Yes	LT Debt/Eq	0.08	EPS Q/Q	-2.09%	Payout	-	Rel Volume	0.49	Prev Close	29.66
Sales Surprise	-	EPS Surprise	-17.47%	Sales Q/Q	-	Earnings	Mar 03 BMO	Avg Volume	1.03M	Price	28.85
SMA20	-12.01%	SMA50	-20.88%	SMA200	-28.36%	Trades		Volume	510,403	Change	-2.73%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-11-25	Initiated	Deutsche Bank	Buy	$65
Sep-16-24	Initiated	Jefferies	Buy	$57
Sep-04-24	Initiated	Bernstein	Outperform	$55
Jul-24-24	Initiated	Morgan Stanley	Overweight	$58
Feb-16-24	Initiated	RBC Capital Mkts	Outperform	$62
Feb-06-24	Initiated	UBS	Buy	$59
Dec-22-23	Initiated	H.C. Wainwright	Buy	$50
Dec-08-23	Initiated	Robert W. Baird	Outperform	$58
Jan-24-23	Initiated	SVB Securities	Outperform	$24
Jan-04-23	Initiated	JP Morgan	Overweight	$23
Dec-02-22	Initiated	BTIG Research	Buy	$24
Oct-26-22	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$158 → $27
Oct-12-22	Initiated	Piper Sandler	Overweight	$23
Aug-19-22	Downgrade	Piper Sandler	Overweight → Neutral	$149
Aug-08-22	Downgrade	Wedbush	Outperform → Neutral	$148.50
May-11-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$150
Oct-19-21	Resumed	Morgan Stanley	Equal-Weight	$107 → $145
Aug-10-21	Downgrade	UBS	Buy → Neutral	$108 → $109
Aug-03-21	Reiterated	Canaccord Genuity	Buy	$101 → $150
Mar-11-21	Initiated	UBS	Buy	$108

Show Previous Ratings

Mar-09-25 04:37PM	Biohaven Ltd. (BHVN): Among Stocks with Heavy Insider Buying in 2025 (Insider Monkey)
Mar-07-25 10:31AM	Biohaven price target lowered to $63 from $69 at Morgan Stanley (TipRanks)
Mar-04-25 04:50PM	Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity (Investor's Business Daily)
Mar-03-25 07:31AM	Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300 (PR Newswire) -13.77%
07:30AM	Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
06:42PM	Loading…
Feb-11-25 06:42PM	Why Biohaven Stock Triumphed on Tuesday (Motley Fool) +11.19%
04:11PM	Biohaven Just Hurdled An FDA Setback And Its Moving Lines (Investor's Business Daily)
01:29PM	Why Biohaven (BHVN) Stock Is Rallying Today (Insider Monkey)
07:30AM	Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia (PR Newswire)
Jan-24-25 05:48PM	Pfizer to Pay $60 Million in Kickback, False Claims Settlement (The Wall Street Journal)
Jan-13-25 11:15AM	Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generation Potential Therapy for IgA Nephropathy (PR Newswire)
Jan-12-25 08:04PM	Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs (GlobeNewswire)
Jan-07-25 05:54PM	Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-17-24 02:23PM	Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved with BHV-1300, Gains Analyst Approval (Benzinga) -5.60%
06:06AM	Is Biohaven Ltd. (BHVN) the Best Weight Loss Stock to Buy Now According to Hedge Funds? (Insider Monkey)
07:30AM	Loading…
Dec-16-24 07:30AM	Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates (PR Newswire) +7.72%
Dec-06-24 07:30AM	Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting (PR Newswire)
Nov-25-24 11:51AM	Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study (Benzinga)
07:30AM	Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity (PR Newswire)
Nov-12-24 04:05PM	Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments (PR Newswire)
Oct-07-24 04:13PM	Scholar Rock Jumps 362% On Final-Phase Win In Spinal Muscular Atrophy (Investor's Business Daily) +10.75%
09:41AM	Scholar Rock Catapults By Triple Digits On Final-Phase Win In Spinal Muscular Atrophy (Investor's Business Daily)
Oct-02-24 04:05PM	Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares (PR Newswire)
Oct-01-24 06:00AM	Biohaven Announces Pricing of $250 Million Public Offering of Common Shares (PR Newswire)
Sep-30-24 04:05PM	Biohaven Announces Proposed Public Offering of Common Shares (PR Newswire)
07:30AM	Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine (PR Newswire)
Sep-23-24 07:30AM	Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA) (PR Newswire) +13.74%
Sep-20-24 07:09PM	Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia (PR Newswire)
Aug-08-24 08:21PM	Do Analysts Think That Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Is a Good GLP-1 and Weight Loss Stock to Invest In? (Insider Monkey) +5.93% +6.25%
04:05PM	Biohaven Reports Second Quarter 2024 Financial Results and Recent Business Developments (PR Newswire)
07:00AM	Loading…
Jul-01-24 07:00AM	Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors (GlobeNewswire)
Jun-28-24 10:00AM	The 3 Smartest Healthcare Stocks to Buy With $1K Right Now (InvestorPlace)
May-29-24 07:30AM	Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day (PR Newswire) -12.57%
07:15AM	Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors (PR Newswire)
May-15-24 11:00AM	Director Gregory Bailey Acquires 15,000 Shares of Biohaven Ltd (BHVN) (GuruFocus.com)
May-14-24 09:35AM	Down -24.55% in 4 Weeks, Here's Why Biohaven Ltd. (BHVN) Looks Ripe for a Turnaround (Zacks) +10.24%
May-13-24 09:35AM	Down -32.76% in 4 Weeks, Here's Why Biohaven Ltd. (BHVN) Looks Ripe for a Turnaround (Zacks) -5.35%
May-09-24 11:54PM	BHVN Stock Earnings: Biohaven Misses EPS for Q1 2024 (InvestorPlace) -13.71%
04:05PM	Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments (PR Newswire)
May-01-24 02:38PM	Shhh! 3 Secret Biotech Stocks Flying Below Wall Street's Radar (InvestorPlace)
Apr-26-24 06:00AM	3 Biotech Stocks to Buy on the Dip: April 2024 (InvestorPlace)
Apr-25-24 11:00AM	Director Gregory Bailey Acquires 25,503 Shares of Biohaven Ltd (BHVN) (GuruFocus.com)
Apr-23-24 11:00AM	Director Gregory Bailey Acquires 48,780 Shares of Biohaven Ltd (BHVN) (GuruFocus.com)
Apr-22-24 04:05PM	Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares (PR Newswire)
Apr-18-24 06:00AM	Biohaven Announces Pricing of $230 Million Public Offering of Common Shares (PR Newswire)
Apr-17-24 04:05PM	Biohaven Announces Proposed Public Offering of Common Shares (PR Newswire)
Apr-13-24 09:00AM	Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates (PR Newswire)
Apr-03-24 10:03PM	LLY, REGN, BHVN: Which Biotech Stock Offers the Most Upside? (TipRanks)
Feb-29-24 04:05PM	Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments (PR Newswire)
Jan-25-24 05:31PM	Stocks to Watch: 3 Companies Working on Next-Gen Weight Loss Drugs (InvestorPlace)
Jan-22-24 07:00AM	Obesity Drugs Lead to Muscle LossPharma Companies Want to Fix That (The Wall Street Journal) +9.24%
Jan-08-24 07:30AM	Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therapeutic Indications in Neuroscience, Immunology and Oncology (PR Newswire) +10.50%
Jan-02-24 07:00AM	Biohaven to Present at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-31-23 03:01AM	Director Irina Antonijevic Sells 11,000 Shares of Biohaven Ltd (BHVN) (GuruFocus.com)
Dec-01-23 04:30PM	Biohaven Presents Expanded EEG and Safety Data for BHV-7000 at the American Epilepsy Society Annual Meeting (PR Newswire)
Nov-16-23 09:40AM	Is Biohaven Ltd. (BHVN) Outperforming Other Medical Stocks This Year? (Zacks)
Nov-14-23 09:15PM	Biohaven Ltd (BHVN) Reports Q3 2023 Financial Results: Advances in Clinical Programs and Strong ... (GuruFocus.com)
04:05PM	Biohaven Reports Third Quarter 2023 Financial Results and Recent Business Developments (PR Newswire)
Nov-06-23 08:50AM	Biohaven Ltd. (BHVN) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks) -6.39%
Oct-31-23 09:40AM	Are Medical Stocks Lagging Biohaven Ltd. (BHVN) This Year? (Zacks)
Oct-19-23 08:50AM	Here's Why Momentum in Biohaven Ltd. (BHVN) Should Keep going (Zacks)
Oct-16-23 07:00AM	Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek (PR Newswire)
Oct-06-23 01:01PM	Insider Buying: CFO Matthew Buten Acquires 22,727 Shares of Biohaven Ltd (BHVN) (GuruFocus.com)
Oct-05-23 04:05PM	Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares (PR Newswire) +5.32%
Oct-03-23 08:50AM	Here's What Could Help Biohaven Ltd. (BHVN) Maintain Its Recent Price Strength (Zacks)
Oct-02-23 11:56PM	Biohaven Announces Pricing of $225 Million Public Offering of Common Shares (PR Newswire) -7.46%
04:36PM	BIOHAVEN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES (PR Newswire)
Sep-29-23 10:00AM	Small Biotech Stocks Haven't Shined of Late, but I Think These 3 Could Be Stars (TheStreet.com)
10:00AM	3 Small Biotech Stocks That Could Be Stars (TheStreet.com)
Sep-28-23 07:53AM	Biohaven (BHVN) Up on Positive Data from Autoimmune Disease Drug (Zacks) +10.54%
Sep-27-23 04:09PM	Biohaven, Yet Another Rival To Argenx In Autoimmune Drugs, Just Rocketed 33% (Investor's Business Daily) +33.31%
12:25PM	Biohaven, Yet Another Argenx Rival In Autoimmune Drugs, Just Rocketed 29% (Investor's Business Daily)
12:00PM	Why Biohaven Stock Is Skyrocketing Today (Motley Fool)
Sep-14-23 07:00AM	Biohaven Completes Enrollment in Pivotal Phase 3 Study of Taldefgrobep Alfa in Spinal Muscular Atrophy (PR Newswire)
Sep-05-23 07:00AM	Biohaven Announces Positive Data from its Exploratory Electroencephalogram (EEG) Biomarker Study of BHV-7000, Completion of Once-Daily Formulation Development, and Plan to Initiate Phase 3 Pivotal Studies (PR Newswire) -6.18%
Aug-09-23 06:01AM	Independent Director of Biohaven Picks Up 1.8% More Stock (Simply Wall St.)
Jul-31-23 09:31AM	Biohaven's Taldefgrobep Alfa Receives EU Orphan Drug Designation for Spinal Muscular Atrophy (PR Newswire)
06:59AM	Biohaven Reports Second Quarter 2023 Financial Results and Recent Business Developments (PR Newswire)
Jul-27-23 12:50PM	Why Biohaven Stock Is Crashing Today (Motley Fool) -22.61%
07:00AM	Biohaven Provides Preliminary EEG Data Update for Kv7 Platform, Regulatory Update on Troriluzole and Other Corporate Updates (PR Newswire)
Jun-27-23 05:31AM	2 Growth Stocks With Major Incoming Catalysts (Motley Fool)
Jun-02-23 09:11AM	Why Biohaven Stock Caught Fire This Week (Motley Fool)
Jun-01-23 04:08PM	Biohaven, A Top 2% Stock, Exits 'Stealth Mode' And Hits A Record High (Investor's Business Daily) +18.39%
01:01PM	How Biohaven Is Coming 'Out Of Stealth Mode' And Bullishly Extending A 4-Day Run (Investor's Business Daily)
11:29AM	Biohaven (BHVN) Stock up 8% on Encouraging Pipeline Updates (Zacks)
May-31-23 07:00AM	Biohaven Provides Overview of Clinical Progress, Regulatory Updates, and Pipeline Developments at R&D Day (PR Newswire) +7.56%
May-25-23 05:00PM	Biohaven to Present R&D Day at Yale School of Management (PR Newswire)
May-24-23 01:30PM	These Small-Cap Biotech Stocks Have the Wind at Their Back (TheStreet.com) -5.34%
May-12-23 04:30PM	Biohaven Reports First Quarter 2023 Financial Results and Reports Recent Business Developments (PR Newswire) +6.91%
May-05-23 10:43AM	Is Biohaven (NYSE:BHVN) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Apr-17-23 07:00AM	Biohaven Expands Executive Leadership Team with Appointment of Nick Kozauer M.D. as Senior Vice President for Clinical Development and Regulatory Strategy (PR Newswire) +9.01%
Mar-30-23 09:40AM	Is Biohaven Ltd. (BHVN) Stock Outpacing Its Medical Peers This Year? (Zacks)
Mar-25-23 09:22AM	Bullish Biohaven Ltd. (NYSE:BHVN) insiders filled their treasuries with US$37m worth of stock over last year (Simply Wall St.)
Mar-23-23 04:05PM	Biohaven Reports Fourth Quarter and Full Year 2022 Financial Results and Reports Recent Business Developments (PR Newswire) +6.64%
11:09AM	Biohaven (BHVN) Acquires Dual Inhibitor for Brain Disorders (Zacks)
Mar-22-23 07:30AM	Biohaven Acquires Exclusive License for Oral, Brain-Penetrant, Dual TYK2/JAK1 Inhibitor for Immune-Mediated Brain Disorders (PR Newswire) -5.89%
Mar-14-23 07:30AM	Biohaven Announces Presentation at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting (PR Newswire)
Mar-13-23 11:39AM	Pfizer (PFE) Gets FDA Nod for Migraine Nasal Spray Zavzpret (Zacks) +7.48%
Feb-23-23 08:36AM	Why Earnings Season Could Be Great for Biohaven (BHVN) (Zacks)
Feb-21-23 07:30AM	Biohaven's Taldefgrobep Alfa Receives FDA Fast Track Designation for Spinal Muscular Atrophy (PR Newswire) -7.69%

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
CHILDS JOHN W	Director	Mar 04 '25	Buy	30.47	32,700	996,238	2,320,571	Mar 05 07:01 AM
Car Bruce	Chief Scientific Officer	Jan 05 '25	Option Exercise	0.00	4,750	0	7,133	Jan 07 08:51 PM
Gentile Kimberly	SVP, Clinical Operations	Jan 05 '25	Option Exercise	0.00	3,750	0	99,719	Jan 07 08:50 PM
Clark George C.	VP, Chief Accounting Officer	Jan 05 '25	Option Exercise	0.00	2,500	0	66,168	Jan 07 08:50 PM
Buten Matthew	Chief Financial Officer	Jan 05 '25	Option Exercise	0.00	4,250	0	196,013	Jan 07 08:49 PM
Coric Vlad	Chief Executive Officer	Jan 05 '25	Option Exercise	0.00	14,250	0	1,803,409	Jan 07 08:48 PM
CHILDS JOHN W	Director	Dec 30 '24	Buy	35.94	29,000	1,042,393	2,368,741	Dec 31 07:00 AM
CHILDS JOHN W	Director	Oct 02 '24	Buy	47.50	21,052	999,970	21,052	Oct 03 07:01 AM
Coric Vlad	Chief Executive Officer	Oct 02 '24	Buy	47.50	21,052	999,970	861,942	Oct 03 07:00 AM
Bailey Gregory	Director	Sep 24 '24	Buy	44.19	5,000	220,966	1,620,071	Sep 25 07:30 AM
CHILDS JOHN W	Director	Jul 18 '24	Buy	35.67	28,400	1,012,983	2,339,741	Jul 19 08:56 AM
Car Bruce	Chief Scientific Officer	Jun 17 '24	Buy	33.58	30,000	1,007,490	30,000	Jun 20 07:30 AM
CHILDS JOHN W	Director	May 30 '24	Buy	35.58	28,000	996,240	2,311,341	May 31 09:04 AM
Bailey Gregory	Director	May 13 '24	Buy	34.19	15,000	512,877	1,615,071	May 15 07:31 AM
CHILDS JOHN W	Director	May 13 '24	Buy	35.17	28,500	1,002,470	2,283,341	May 14 07:30 AM
Bailey Gregory	Director	Apr 24 '24	Buy	39.18	25,503	999,169	1,600,071	Apr 25 07:32 AM
Bailey Gregory	Director	Apr 22 '24	Buy	41.00	48,780	1,999,980	1,574,568	Apr 23 07:54 AM
CHILDS JOHN W	Director	Apr 22 '24	Buy	41.00	195,121	7,999,961	4,096,512	Apr 23 07:54 AM
Coric Vlad	Chief Executive Officer	Apr 22 '24	Buy	41.00	121,951	4,999,991	1,788,417	Apr 23 07:54 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BHVN

Biohaven Ltd

Upgrade your FINVIZ experience